Developer docs
API playgroundTry for free, no card

Search company profiles

ProJect Pharmaceutics

Full company profile

uuid000np6i

Namestring
ProJect Pharmaceutics
Legal namestring
ProJect Pharmaceutics GmbH
Company typeenum
Private
Founded yearint
2010
Descriptiontext

ProJect Pharmaceutics GmbH, founded in 2010 in Martinsried near Munich, Germany, is a contract research organization (CRO) that delivers formulation and process development services for injectable parenteral drug products. The company specializes in technically demanding modalities — proteins, peptides, antibody-drug conjugates (ADCs), N-mustard cytotoxic drugs, liposomal systems, and live viral / gene-and-cell-therapy products (up to BSL-2 and GMO S2). Its technical foundation rests on a Quality-by-Design methodological base plus proprietary capabilities including Predictive Formulation Analytics (high-throughput screening via DLS, CG-MALS, and nanoDSC), Controlled Nucleation Technology, and Critical Pressure Scanning for lyophilization process optimization. The company operates dedicated OEL4 cytotoxic and BSL-2 viral safety laboratories, develops efficient lyophilization cycles that are described as reducible to a maximum of five cycles with secondary-drying sampling capability, and — as of December 2025 — extends analytical capacity with an Orbitrap Exploris 240 LC-MS system for multi-attribute analysis and native DAR determination of mAbs and ADCs.

ProJect Pharmaceutics monetizes exclusively through professional-services contracts (project-based fees), serving three principal customer segments: large biopharmaceutical companies, biotechnology firms developing novel biologics and ADCs, and CDMOs requiring formulation and lyophilization process development for client programs. Customer reach spans Europe (Germany, France, UK, Switzerland, Italy), the United States, and Asia Pacific (with BiGEN Co., Ltd. operating a Seoul-based Asian representative office routing inquiries back to the German HQ). Technology partnerships include LYOCONTRACT (GMP fill-finish manufacturing), Hof Sonderanlagenbau (pilot freeze dryers), and Teclen (Lyoprotect single-use bag systems). The company has developed formulations for over 25 ADCs with international top-tier pharmaceutical sponsors and runs regulatory-acceptable documentation (ICH, WHO, GLP-like, ISO) suitable for client submissions.

In September 2025, ProJect Pharmaceutics entered a partnership with Munich- and Frankfurt-based private equity firm Afinum Management GmbH to support its next phase of growth; founders Dr. Andreas Schütz and Klaus Hellerbrand remain as substantial co-investors and managing directors. The partnership is explicitly oriented toward international customer base expansion, service portfolio broadening, and targeted acquisitions. The firm also holds US Patent No. 11,752,135 (granted October 2023) covering a novel liquid formulation that stabilizes Bendamustine and related N-mustard anticancer agents at room temperature for up to 24 months.

Short descriptiontext

ProJect Pharmaceutics is a German CRO founded in 2010 that delivers formulation, lyophilization, and analytical process development for injectable parenteral drug products — including biologics, ADCs, cytotoxics, and viral therapeutics — serving biopharma, biotech, and CDMO clients across Europe, the US, and Asia from its Martinsried headquarters.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlanegg, Germany
HQ citystring
Planegg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
parenteral formulation development, lyophilization process development, ADC formulation services, biologics contract research, cytotoxic drug development
Industry4 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

CRO services for formulation and process development of injectable parenteral drug products, including drug substance and drug product development, lyophilization cycle development, analytical services, and technology transfer support. Revenue generated through project-based professional services contracts.

project-pharmaceutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ProJect Pharmaceutics provides formulation and lyophilization process development services for injectable parenteral drug products including proteins, peptides, ADCs, cytotoxic drugs, viral therapeutics, gene/cell therapies, vaccines, and liposomal systems. Operating as a CRO, the company offers drug substance and drug product development, lyophilization cycle development, analytical services, aseptic non-GMP preclinical manufacturing, in-use stability studies, and technology transfer to GMP manufacturing for biopharma, biotech, and CDMO clients worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces lyophilization cycle development to 5 cycles maximum using algorithm-based approach
+1 more record
Product overview1 text field

ProJect Pharmaceutics is a contract research organization (CRO) offering a comprehensive portfolio of formulation and process development services for injectable parenteral drug products. The core offerings include Drug Formulation Development, ADC Formulation Development, Cytotoxic Drug Development, and High Protein Concentration Formulations, supported by specialized Lyophilization Process Development (including Bulk Lyophilization Development) and Analytical Services and Method Development. Additional services encompass Aseptic Preclinical Batch Manufacturing, In-use Stability Studies, Downstream Process Development, Technology Transfer to Fill&Finish, Liposomal Formulation Development, and Live Viral Therapeutics/Gene & Cell Therapy/Vaccine development. A notable free service offering is the 'Check your Lyo Cycle' assessment for lyophilization optimization. The company operates dedicated cytotoxic safety laboratories (OEL4 and BSL-2) and has developed proprietary Predictive Formulation Analytics technology for accelerated formulation screening.

Product and service15 records
1Drug Formulation Development
CategoryFormulation Development
Description

Quality-by-Design based development of parenteral formulations and innovative drug delivery systems for biopharmaceutics, cytotoxics, and viral/non-viral nanoparticular systems, delivered as a CRO service to pharmaceutical and biotech clients.

2ADC Formulation Development
CategoryFormulation Development
Description

Innovative formulation and lyophilization process development for Antibody Drug Conjugates (ADCs), combining protein formulation and process expertise with cytotoxic drug knowledge to overcome ADC-specific stability challenges for biopharma and biotech clients.

3Cytotoxic Drug Development
CategoryFormulation Development
Description

Formulation and lyophilization process development for cytotoxic and highly potent drugs including small molecules, generics, and Antibody Drug Conjugates used as anti-cancer therapeutics, leveraging dedicated OEL4 safety laboratories.

4High Protein Concentration Formulations
CategoryFormulation Development
Description

Science-based development of high protein formulations for convenient use in pre-filled syringes, cartridges, and dual chamber systems, characterized by reduced aggregation, low viscosity, and smooth syringeability for biologic therapeutics.

5Lyophilization Process Development
CategoryLyophilization Process Development
Description

Development of efficient and robust freeze drying cycles for GMP manufacturing of all freeze-dried drug products, using high-end HOF pilot freeze dryers with process analytical technologies (PAT) including proprietary Controlled Nucleation and Critical Pressure Scanning technologies.

6Bulk Lyophilization Development
CategoryLyophilization Process Development
Description

Evaluation of critical bulk freeze-drying parameters and development of freeze drying cycles for bulk APIs or investigational bulk drug intermediates to obtain solid lyophilized cake or free-flowing lyophilized powder.

7Aseptic Preclinical Batch Manufacturing
CategoryManufacturing Services
Description

Non-GMP pilot batch manufacturing of pre-clinical batches for liquid and lyophilized drug delivery systems with assured sterility through permeable lyophilization bags, supported by valid documentation for pre-clinical study supply or Tox batch supply.

8In-use Stability Studies
CategoryAnalytical and Stability Services
Description

Evaluation of handling, material compatibility, and stability of injectable drug products during intended use in clinical trials, including compatibility with infusion media, storage stability, administration simulation, and adsorption evaluation.

9Technology Transfer to Fill & Finish
CategoryManufacturing Services
Description

Facilitation of technology transfer from development to GMP manufacturing, including primary packaging selection, container closure system compatibility, process mock-up studies, and scale-up support, often delivered in partnership with LYOCONTRACT.

10Analytical Services and Method Development
CategoryAnalytical and Stability Services
Description

In-depth analytical characterization of drug substance and drug product stability using state-of-the-art equipment including LC-MS, chromatography systems, spectroscopy, and thermal analysis for ICH stability testing.

11Downstream Process Development
CategoryProcess Development
Description

Rational design of cell harvest and protein purification steps in biologics drug substance manufacturing using Predictive Formulation Analytics to optimize chromatographic steps and avoid downstream processing product loss through aggregation or degradation.

12Liposomal Formulation Development
CategoryFormulation Development
Description

Innovative GMP-compatible process for liposomal encapsulation of APIs and manufacturing of drug-loaded, lyophilized liposomes with high encapsulation efficiency, compatible with biomolecules and standard fill & finish equipment.

13Live Viral Therapeutics, Gene and Cell Therapy Products and Vaccines
CategoryFormulation Development
Description

Formulation and lyophilization process development for gene and cell therapy products, live virus drugs, vaccine formulations, viral vectors (adenovirus, AAV, lentivirus), VLPs, and bacteriophages with safety requirements up to GMO S2 and BSL-2.

14Check your Lyo Cycle Service
CategoryConsulting Services
Description

Free expert analysis of existing lyophilization cycles to identify optimization potential, product quality risks, technical weaknesses, scale-up risks, and opportunities for cycle length reduction.

15Excipient Quantification Service
CategoryAnalytical and Stability Services
Description

Analytical service offering for quantification of excipients including sugars, sugar alcohols, amino acids, detergents, buffer substances, antioxidants, and inorganic components using chromatographic and spectroscopic analysis methods.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

BiGEN serves as Asian representative office of ProJect Pharmaceutics GmbH, providing local support and forwarding inquiries from Asian customers. Located in Seoul, Republic of Korea, BiGEN acts as the primary point of contact for Asian market engagement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to provide pharmaceutical industry with high quality parenterals from clinical to large scale commercial scale. LYOCONTRACT operates state-of-the-art pharmaceutical manufacturing site with capabilities for liquid and freeze-dried parenteral drugs production.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialized CDMO offering drug product formulation, lyophilization cycle development, and analytical services for injectables and complex molecules, closely mirroring ProJect's core offering in small-batch aseptic and CMC enablement.

TypeDirect peer
Description

Established CDMO specializing in aseptic fill-finish, lyophilization, and complex injectable drug products; competes for the same formulation-to-fill-finish hand-off programs as ProJect.

TypeDirect peer
Description

Global CDMO with biologics formulation, fill-finish and analytical services including for complex modalities, operating at much larger scale across mammalian and microbial platforms.

4Recipharm
TypeDirect peer
Description

CDMO with injectables and lyophilization capabilities serving biologics and small molecules across sterile fill-finish; a partner-competitor for late-phase tech-transfer work.

TypeDirect peer
Description

Pharmaceutical services provider spanning formulation development, analytical services, and clinical manufacturing for sterile drug products, including lyophilized injectables.

TypeBroad incumbent
Description

Largest pure-play CDMO with biologics formulation, fill-finish, and ADC capabilities operating at global scale; offers overlapping services within a much wider portfolio and competes on enterprise programs.

TypeBroad incumbent
Description

Global CDMO with strong injectables, biologics and oral dose capabilities; serves as a dominant incumbent that sponsors often consider before specialty CROs like ProJect.

TypeBroad incumbent
Description

Integrated CDMO with sterile injectables, lyophilization, and biologics development services; competes for client share in formulation, tech transfer, and fill-finish.

TypeBroad incumbent
Description

Large analytical-services and contract research network with significant pharmaceutical CMC/formulation testing capability relevant to ProJect's analytical services offering.

TypeBroad incumbent
Description

Biologics safety testing and CMC services arm of Merck KGaA; serves similar biopharma clients for analytical testing and biosafety support and competes for portions of ProJect's analytical/CMC scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProJect Pharmaceutics

Pharmaceutical Contract Research Servicesproject-pharmaceutics.com

ProJect Pharmaceutics is a German CRO founded in 2010 that delivers formulation, lyophilization, and analytical process development for injectable parenteral drug products — including biologics, ADCs, cytotoxics, and viral therapeutics — serving biopharma, biotech, and CDMO clients across Europe, the US, and Asia from its Martinsried headquarters.

What ProJect Pharmaceutics does

ProJect Pharmaceutics GmbH, founded in 2010 in Martinsried near Munich, Germany, is a contract research organization (CRO) that delivers formulation and process development services for injectable parenteral drug products. The company specializes in technically demanding modalities — proteins, peptides, antibody-drug conjugates (ADCs), N-mustard cytotoxic drugs, liposomal systems, and live viral / gene-and-cell-therapy products (up to BSL-2 and GMO S2). Its technical foundation rests on a Quality-by-Design methodological base plus proprietary capabilities including Predictive Formulation Analytics (high-throughput screening via DLS, CG-MALS, and nanoDSC), Controlled Nucleation Technology, and Critical Pressure Scanning for lyophilization process optimization. The company operates dedicated OEL4 cytotoxic and BSL-2 viral safety laboratories, develops efficient lyophilization cycles that are described as reducible to a maximum of five cycles with secondary-drying sampling capability, and — as of December 2025 — extends analytical capacity with an Orbitrap Exploris 240 LC-MS system for multi-attribute analysis and native DAR determination of mAbs and ADCs.

ProJect Pharmaceutics monetizes exclusively through professional-services contracts (project-based fees), serving three principal customer segments: large biopharmaceutical companies, biotechnology firms developing novel biologics and ADCs, and CDMOs requiring formulation and lyophilization process development for client programs. Customer reach spans Europe (Germany, France, UK, Switzerland, Italy), the United States, and Asia Pacific (with BiGEN Co., Ltd. operating a Seoul-based Asian representative office routing inquiries back to the German HQ). Technology partnerships include LYOCONTRACT (GMP fill-finish manufacturing), Hof Sonderanlagenbau (pilot freeze dryers), and Teclen (Lyoprotect single-use bag systems). The company has developed formulations for over 25 ADCs with international top-tier pharmaceutical sponsors and runs regulatory-acceptable documentation (ICH, WHO, GLP-like, ISO) suitable for client submissions.

In September 2025, ProJect Pharmaceutics entered a partnership with Munich- and Frankfurt-based private equity firm Afinum Management GmbH to support its next phase of growth; founders Dr. Andreas Schütz and Klaus Hellerbrand remain as substantial co-investors and managing directors. The partnership is explicitly oriented toward international customer base expansion, service portfolio broadening, and targeted acquisitions. The firm also holds US Patent No. 11,752,135 (granted October 2023) covering a novel liquid formulation that stabilizes Bendamustine and related N-mustard anticancer agents at room temperature for up to 24 months.

ProJect Pharmaceutics firmographics

Firmographics
Name
ProJect Pharmaceutics
Legal name
ProJect Pharmaceutics GmbH
Website
https://project-pharmaceutics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
ProJect Pharmaceutics is a German CRO founded in 2010 that delivers formulation, lyophilization, and analytical process development for injectable parenteral drug products — including biologics, ADCs, cytotoxics, and viral therapeutics — serving biopharma, biotech, and CDMO clients across Europe, the US, and Asia from its Martinsried headquarters.
Ownership category
akta.pro rank

ProJect Pharmaceutics industry classification

Industry
Product category
Pharmaceutical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Parenteral formulation development
  • Lyophilization process development
  • ADC formulation services
  • Biologics contract research
  • Cytotoxic drug development

Where ProJect Pharmaceutics is headquartered

Location

Headquarters

HQ city
Planegg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

ProJect Pharmaceutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services: CRO services for formulation and process development of injectable parenteral drug products, including drug substance and drug product development, lyophilization cycle development, analytical services, and technology transfer support. Revenue generated through project-based professional services contracts.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

ProJect Pharmaceutics product offering

Product offering

Core offering

ProJect Pharmaceutics provides formulation and lyophilization process development services for injectable parenteral drug products including proteins, peptides, ADCs, cytotoxic drugs, viral therapeutics, gene/cell therapies, vaccines, and liposomal systems. Operating as a CRO, the company offers drug substance and drug product development, lyophilization cycle development, analytical services, aseptic non-GMP preclinical manufacturing, in-use stability studies, and technology transfer to GMP manufacturing for biopharma, biotech, and CDMO clients worldwide.

Product overview

ProJect Pharmaceutics is a contract research organization (CRO) offering a comprehensive portfolio of formulation and process development services for injectable parenteral drug products. The core offerings include Drug Formulation Development, ADC Formulation Development, Cytotoxic Drug Development, and High Protein Concentration Formulations, supported by specialized Lyophilization Process Development (including Bulk Lyophilization Development) and Analytical Services and Method Development. Additional services encompass Aseptic Preclinical Batch Manufacturing, In-use Stability Studies, Downstream Process Development, Technology Transfer to Fill&Finish, Liposomal Formulation Development, and Live Viral Therapeutics/Gene & Cell Therapy/Vaccine development. A notable free service offering is the 'Check your Lyo Cycle' assessment for lyophilization optimization. The company operates dedicated cytotoxic safety laboratories (OEL4 and BSL-2) and has developed proprietary Predictive Formulation Analytics technology for accelerated formulation screening.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Formulation Development Quality-by-Design based development of parenteral formulations and innovative drug delivery systems for biopharmaceutics, cytotoxics, and viral/non-viral nanoparticular systems, delivered as a CRO service to pharmaceutical and biotech clients.
  • ADC Formulation Development Innovative formulation and lyophilization process development for Antibody Drug Conjugates (ADCs), combining protein formulation and process expertise with cytotoxic drug knowledge to overcome ADC-specific stability challenges for biopharma and biotech clients.
  • Cytotoxic Drug Development Formulation and lyophilization process development for cytotoxic and highly potent drugs including small molecules, generics, and Antibody Drug Conjugates used as anti-cancer therapeutics, leveraging dedicated OEL4 safety laboratories.
  • High Protein Concentration Formulations Science-based development of high protein formulations for convenient use in pre-filled syringes, cartridges, and dual chamber systems, characterized by reduced aggregation, low viscosity, and smooth syringeability for biologic therapeutics.
  • Lyophilization Process Development Development of efficient and robust freeze drying cycles for GMP manufacturing of all freeze-dried drug products, using high-end HOF pilot freeze dryers with process analytical technologies (PAT) including proprietary Controlled Nucleation and Critical Pressure Scanning technologies.
  • Bulk Lyophilization Development Evaluation of critical bulk freeze-drying parameters and development of freeze drying cycles for bulk APIs or investigational bulk drug intermediates to obtain solid lyophilized cake or free-flowing lyophilized powder.
  • Aseptic Preclinical Batch Manufacturing Non-GMP pilot batch manufacturing of pre-clinical batches for liquid and lyophilized drug delivery systems with assured sterility through permeable lyophilization bags, supported by valid documentation for pre-clinical study supply or Tox batch supply.
  • In-use Stability Studies Evaluation of handling, material compatibility, and stability of injectable drug products during intended use in clinical trials, including compatibility with infusion media, storage stability, administration simulation, and adsorption evaluation.
  • Technology Transfer to Fill & Finish Facilitation of technology transfer from development to GMP manufacturing, including primary packaging selection, container closure system compatibility, process mock-up studies, and scale-up support, often delivered in partnership with LYOCONTRACT.
  • Analytical Services and Method Development In-depth analytical characterization of drug substance and drug product stability using state-of-the-art equipment including LC-MS, chromatography systems, spectroscopy, and thermal analysis for ICH stability testing.
  • Downstream Process Development Rational design of cell harvest and protein purification steps in biologics drug substance manufacturing using Predictive Formulation Analytics to optimize chromatographic steps and avoid downstream processing product loss through aggregation or degradation.
  • Liposomal Formulation Development Innovative GMP-compatible process for liposomal encapsulation of APIs and manufacturing of drug-loaded, lyophilized liposomes with high encapsulation efficiency, compatible with biomolecules and standard fill & finish equipment.
  • Live Viral Therapeutics, Gene and Cell Therapy Products and Vaccines Formulation and lyophilization process development for gene and cell therapy products, live virus drugs, vaccine formulations, viral vectors (adenovirus, AAV, lentivirus), VLPs, and bacteriophages with safety requirements up to GMO S2 and BSL-2.
  • Check your Lyo Cycle Service Free expert analysis of existing lyophilization cycles to identify optimization potential, product quality risks, technical weaknesses, scale-up risks, and opportunities for cycle length reduction.
  • Excipient Quantification Service Analytical service offering for quantification of excipients including sugars, sugar alcohols, amino acids, detergents, buffer substances, antioxidants, and inorganic components using chromatographic and spectroscopic analysis methods.

Quantifiable outcome

  • Reduces lyophilization cycle development to 5 cycles maximum using algorithm-based approach
  • +1 more outcomes

Companies that use ProJect Pharmaceutics

Customer profile

Segments3 records

Ideal customer profiles3 records

ProJect Pharmaceutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

ProJect Pharmaceutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BiGEN Co., Ltd.coreChannel Partner/ Reseller/ DistributorBiGEN serves as Asian representative office of ProJect Pharmaceutics GmbH, providing local support and forwarding inquiries from Asian customers. Located in Seoul, Republic of Korea, BiGEN acts as the primary point of contact for Asian market engagement.
  • LYOCONTRACTcoreStrategic or Co-development PartnerStrategic partnership to provide pharmaceutical industry with high quality parenterals from clinical to large scale commercial scale. LYOCONTRACT operates state-of-the-art pharmaceutical manufacturing site with capabilities for liquid and freeze-dried parenteral drugs production.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

ProJect Pharmaceutics competitors and assessment

Company assessment

Direct peers

  • Ardena: Specialized CDMO offering drug product formulation, lyophilization cycle development, and analytical services for injectables and complex molecules, closely mirroring ProJect's core offering in small-batch aseptic and CMC enablement.
  • Vetter Pharma: Established CDMO specializing in aseptic fill-finish, lyophilization, and complex injectable drug products; competes for the same formulation-to-fill-finish hand-off programs as ProJect.
  • AGC Biologics: Global CDMO with biologics formulation, fill-finish and analytical services including for complex modalities, operating at much larger scale across mammalian and microbial platforms.
  • Recipharm: CDMO with injectables and lyophilization capabilities serving biologics and small molecules across sterile fill-finish; a partner-competitor for late-phase tech-transfer work.
  • Almac Group: Pharmaceutical services provider spanning formulation development, analytical services, and clinical manufacturing for sterile drug products, including lyophilized injectables.

Broad incumbents

  • Lonza: Largest pure-play CDMO with biologics formulation, fill-finish, and ADC capabilities operating at global scale; offers overlapping services within a much wider portfolio and competes on enterprise programs.
  • Catalent: Global CDMO with strong injectables, biologics and oral dose capabilities; serves as a dominant incumbent that sponsors often consider before specialty CROs like ProJect.
  • Piramal Pharma Solutions: Integrated CDMO with sterile injectables, lyophilization, and biologics development services; competes for client share in formulation, tech transfer, and fill-finish.
  • Eurofins CDMO: Large analytical-services and contract research network with significant pharmaceutical CMC/formulation testing capability relevant to ProJect's analytical services offering.
  • BioReliance (Merck KGaA): Biologics safety testing and CMC services arm of Merck KGaA; serves similar biopharma clients for analytical testing and biosafety support and competes for portions of ProJect's analytical/CMC scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

ProJect Pharmaceutics social profiles

Digital presence

ProJect Pharmaceutics compliance and trust

Trust signal

Compliance4 records

ProJect Pharmaceutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProJect Pharmaceutics leadership team

Management profile

Number of profiles

Profiles2 records

ProJect Pharmaceutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProJect Pharmaceutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProJect Pharmaceutics

What does ProJect Pharmaceutics do?

ProJect Pharmaceutics provides formulation and lyophilization process development services for injectable parenteral drug products including proteins, peptides, ADCs, cytotoxic drugs, viral therapeutics, gene/cell therapies, vaccines, and liposomal systems. Operating as a CRO, the company offers drug substance and drug product development, lyophilization cycle development, analytical services, aseptic non-GMP preclinical manufacturing, in-use stability studies, and technology transfer to GMP manufacturing for biopharma, biotech, and CDMO clients worldwide.

Is ProJect Pharmaceutics a public or private company?

ProJect Pharmaceutics is a private company. It is classified as private equity controlled and is currently operating.

When was ProJect Pharmaceutics founded?

ProJect Pharmaceutics was founded in 2010. It employs 11 to 50 people.

Where is ProJect Pharmaceutics based?

ProJect Pharmaceutics is headquartered in Planegg, Germany, in the Europe region.

How does ProJect Pharmaceutics make money?

One revenue line is on record: contract Research Services.

Who are ProJect Pharmaceutics's main competitors?

Direct peers on record are Ardena, Vetter Pharma, AGC Biologics, Recipharm and Almac Group. Broad incumbents are Lonza, Catalent, Piramal Pharma Solutions, Eurofins CDMO and BioReliance (Merck KGaA).

Does ProJect Pharmaceutics have an API?

No public API is recorded for ProJect Pharmaceutics.

What industry is ProJect Pharmaceutics in?

ProJect Pharmaceutics's product category is Pharmaceutical Contract Research Services. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales